Innovation Inducement Prizes
On July 14, 2009, at the WIPO Conference on Intellectual Property and Public Policy Issues, Michael Kock (Global Head IP Seeds and Biotechnology at Syngenta International AG) underscored that today’s global challenges can only dealt with in an efficient manner by creating innovation networks which included the reward of substantial amounts of money to solve technical challenges and problems.
At the WIPO Conference on Intellectual Property and Public Policy Issues today, Margaret Chan, the Director General of the World Health Organization, made the following speech at WIPO’s Conference on Intellectual Property and Public Policy Issues on the topic of “Strengthening Multilateral Cooperation on IP and Public Health” where she shared the limelight with Pascal Lamy, Director General of the World Trade Organ
I just finished a two day meeting in Manchester, England, in a meeting of Joe Stigltiz’s Initiative for Policy Dialogue (IPD) Task Force on Intellectual Property and Development. The meeting was held at the University of Manchester’s Brooks World Poverty Institute. The agenda and conference papers for the meeting are on the web here, including a paper on prizes I wrote with Tim Hubbard.
Prizes and Grants, Type I, II and III diseases, rich and poor countries, open and closed medicine developmentSubmitted by James Love on 10. May 2009 - 4:42
In efforts to introduce the topic of innovation inducement prizes into the discussions about drug development, there are inevitably questions about the relationship between grants and prizes.
In some cases, prizes are being offered as a reform of “pull” mechanisms, and can usefully be compared to the grant of a marketing monopoly, which is the primary pull mechanism used today. In this context, a question is, should drug or vaccine developers be rewarded with monopolies or cash? And if cash, where does the money come from, and how much money is given to a particular project?
$2 billion and $147 billion: WHO releases detailed costing estimates for implementing WHO IGWG plan of actionSubmitted by thiru on 22. January 2009 - 8:31
On 21 January 2009, WHO released a document (EB124/16 Add.2) relating to the global strategy and plan of action of the public health, innovation and intellectual strand of its work entitled “Proposed time frames and estimated funding needs“. This document is a costing exercise to “estimate funding needs for the implementation of the plan”.
Jan 16-17, 2009. KEI, HAI, MSF, Oxfam, UAEM & IQsensato Roundtable on prizes for Type II & III diseases, GenevaSubmitted by Staff on 15. January 2009 - 23:00
Roundtable on De-linking R&D Incentives from Prices: Designing Innovation Inducement Prizes for Diagnostics, New Drugs and Vaccines for Type II and III diseases and conditions, with a particular focus on TB and Chagas Disease
The meeting is going to be small with around 40 high level policy makers and technical participants, including industry, donors, civil society and government officials.
Yesterday December 1 2008, professors Aidan Hollis and Thomas Pogge presented their Health Impact Fund (HIF) proposal at Georgetown University in Washington, DC.
The meeting convened and moderated by the President of Georgetown University, Jack deGioia, was attended by 50/60 people and was structured with two presentations by the co-authors and a panel discussion by :
Paul Antony, M.D., Chief Medical Officer and Executive Director, PhRMA
Lawrence Gostin, J.D., Associate Dean and Timothy and Linda O’Neill Professor of Global Health Law, Georgetown University Law Center
I have been asked to elaborate on the relationship between the Medical Innovation Prize Fund (S.2210, 110th Congress) and the WTO TRIPS Agreement.
For centuries, innovation inducement prizes have been suggested as a mechanism to stimulate investments in a wide range of topics. (See, for example, Selected Innovation Prizes and Reward Programs, KEI Research Note 2008:1). During most of this period, the patent system has also existed.